Share Name Share Symbol Market Type Share ISIN Share Description
Yourgene Health Plc LSE:YGEN London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.40 2.94% 14.00 5,982,049 16:15:03
Bid Price Offer Price High Price Low Price Open Price
13.50 14.50 14.00 13.60 13.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.61 -3.38 -0.40 101
Last Trade Time Trade Type Trade Size Trade Price Currency
18:36:28 O 200,000 13.70 GBX

Yourgene Health (YGEN) Latest News

More Yourgene Health News
Yourgene Health Investors    Yourgene Health Takeover Rumours

Yourgene Health (YGEN) Discussions and Chat

Yourgene Health Forums and Chat

Date Time Title Posts
20/5/202006:42YourGene to Infinity2,121
04/5/202007:06Partnership with Novacyt 2
30/3/202007:20Yourgene Health at the UK Investor Show3

Add a New Thread

Yourgene Health (YGEN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Yourgene Health trades in real-time

Yourgene Health (YGEN) Top Chat Posts

Yourgene Health Daily Update: Yourgene Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker YGEN. The last closing price for Yourgene Health was 13.60p.
Yourgene Health Plc has a 4 week average price of 13.60p and a 12 week average price of 13.60p.
The 1 year high share price is 23.50p while the 1 year low share price is currently 7.25p.
There are currently 719,509,950 shares in issue and the average daily traded volume is 1,747,031 shares. The market capitalisation of Yourgene Health Plc is £100,731,393.
twix386: My feeling is we should welcome a T/O realistically at 25p++ as otherwise waiting a realistic minimum of 12/18 months would be a gamble. However, it seems odds on that well within that timeframe we will see a sustained market crash with lower lows than 2008/09. I really don't like the gamble waiting infers and would far rather get 25p++ today and end this regularly underperforming share price.I simply cannot envisage any scenario where we have the amount of time needed to grow to 25p+ in time without a T/O and if I'm right we are not going to enhance shareholder value no matter company progress unless that progress is uncharactristically Stella, completely out of past experience AND the market takes notice for a change..... or we get a T/O before an overdue crash starts.The risk is much higher than most gather, even if we are positive on Yourgene share price medium/long term as i otherwise would be. It's my view we should now actively seek a T/O aiming at 30p+ with a floor of 25p. We really can't keep stretching out our timeframes constantly much longer through delays and disappointing communication. Aimho
admak: Definitely hit a note there, and the canary sing! Talk about unintelligent mentality.Covid has impacted the core business, so ygen spins up clarigene. Why get into covid test business if ygen isnt ready to compete? Only idiots will try to counter valid criticisms with '5000% increase' retort. Ygen cant even maintain 0% stagnation, rather in -ve% share price.
ngen yap: There is no positive spin to be made on the performance of the share price! It's underperformed, period. Doesn't mean the company isn't progressing well and that's what I remain confident in. And hopefully share price will take care of itself or we get acquired!RE share options, I'll be disappointed if they are issued at nominal value but these are at market value each time. So company actually gets the cash IF options exercised. A good motivational tool to get share price up for it to be worth anything. E.g. the 18p options are worth nothing at the moment.Anyway, don't fret, it's the weekend. Next week is another trading week.
twix386: Do we think these Results are going to buck the trend of disappointment at a weak or falling share price? My view is without further material newsflow(which we are probably hoping for by way of no Results date notification) we will applaud our progress as always but figures will not be enough to curtail the bigger task required to meet unchanged forecast target and the share price will be weak. Historically it's been a given. So do you feel (newsflow) lucky?
pedr01: "YGEN share price underperforming relative to overall markets, especially since the impediment impacting H1 removed and lots of growth avenues." Not sure that is true. Just a bit of frustration combined with a bit of hindsight investing seeing other (select) companies moving forwards. FTSE100 6541/7604 => -14% FTSE250 20171/22108 => -8.8% FTSE AIM 1069/963 => +11.0% YGEN 16.5/13.88 => +18.9% relative to 02 Jan 2020 Personally, I just re-visit my buy notes and decide whether I think the company has moved forwards or backwards against why I bought in the first place. In my view everything is moving forwards, and if they meet expectations (or even close) and achieve maiden earnings (not just ebitda) then that should start the share price moving forwards. Unfortunately ... having asked the question of whether the forecasts take account of earn-outs the reply was slightly "muddied", and to avoid disappointment I think it is best to assume that forecasts DO NOT account for earn-outs due in the period.
ngen yap: YGEN share price underperforming relative to overall markets, especially since the impediment impacting H1 removed and lots of growth avenues. When I am frustrated with it, I ask myself. Do I like the space YGEN is in? Yes. Do I like it's products and services? Yes. Do I think management can deliver? Yes. Is the company well funded? Yes. Does it have USP/ IP? Yes. Then I always end up adding......hehe.....this will come good. Looking fwd to interim update, numbers won't be great but am hopeful on outlook.
apad: Pretty much my view, Pedr01. I bought in as a recovery play when they stopped funding the lawyers. Like SCRUTABLE I viewed the Covid activity as a great way of subsidising/expanding laboratory capacity, bridging the gap so to speak. Rather than as a great profit maker. I also view the software package very favourably. The major unknown for me is the length of time before the world breaks free from the panic political reaction to covid and hospital activities return to normal. So, I viewed the recent share price as overblown for a recovery play and I don't expect the numbers to be that good in December. So, still a recovery play. YGEN is a 'hold' for me unless LR trumpets a share price increase in which case I might top-slice with a view to buying back after December interims. Still, I've been wrong before 😊 GLA apad
hjb1: Dan, there is no need to go around pumping Ygen shares. The share price will go up without all that sort of nonsense. The imminent news will do the work and uplift the share price
the abbot: What are your thoughts chaps, email to Lyn? On the 25th March Yourgene’s share price hit a high of 25p today we are at sub 17p or thereabouts. Additionally, since the 25th March we have had the following news releases. 1. RNS contract Manufacturing agreement with NCYT. 2. RNS positive presentation on 'adapting during crisis' 3. RNS year eand trading update - Revenues increase 86% 4. RNS Covid-19 testing service launch and a business update. 5. RNS CE-IVD mark received for illumina-based IONA test 6. RNS Collaboration in COVID-19 testing (caxton) 7. RNS Covid-19 assay launched 8. RNS appointment of Joint Broker 9. RNS CE-IVD Mark for ClarigeneT Sars-Cov-2 test 10. RNS £16.15m placing at zero discount and acquisition 11. RNS TGA approval in Australia for IONA Nx sale All RNS'd. 1. Now I would consider any one RNS’s to be received by the market as good news, put together as a group, I consider the group as just so spectacular as to consider the share price might have gone stratospheric. Why do you think it has not? 2. Why is it that you have refused to promote your company surrounding the Covid-19 developments? As a note, every other company that has ‘marketed̵7;, whilst creating a little more volatility, has enabled every one of them, without exception, to raise capital at a vastly increased price and thus reduce dilution to the shareholder. 3. On the basis that very little buying exists in the market for Yourgene’s shares - Please could you explain when and what information was shared with the institutions to get the placing away, did you ever share the same information with the private investors. If yes, why did the institutions buy when the private investors do not? 4. Do you believe that share price growth is an aim of the company,? if yes and none of the 11 points listed above has done anything to support this, what do you plan to do differently to achieve this aim?
phatomtraider: Busted a gut laughing at these share trading experts turning a blind eye to share price being manipulated and shafted by Management. Seems like they've been given a blank cheque by PIs to get away with any level of incompetence on poor communications and low share price growth. PIs here are just praying in the corner "it's okay, it's okay I will still get 50p in a couple years time" when they could've gotten the same share price growth with any other recovery stock or COVID stock this year.
Yourgene Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Yourgene H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210117 17:32:58